Predictors for improvement in patient-reported outcomes: post hoc analysis of a phase 3 randomized, open-label study of eculizumab and ravulizumab in complement inhibitor-naive patients with paroxysmal nocturnal hemoglobinuria |
Oct 2023 |
Annals of Hematology |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
Deciphering treatment patterns in non-severe/moderate aplastic anemia: an international observational study |
Oct 2023 |
Leukemia |
Aplastic Anemia |
Patterns of Diagnostic Evaluation and Determinants of Treatment in Older Patients With Non-transfusion Dependent Myelodysplastic Syndromes |
Oct 2023 |
Oncologist |
Myelodysplastic Syndromes (MDS) |
Eltrombopag for Low-Risk Myelodysplastic Syndromes With Thrombocytopenia: Interim Results of a Phase II, Randomized, Placebo-Controlled Clinical Trial (EQOL-MDS) |
Oct 2023 |
Journal of Clinical Oncology |
Myelodysplastic Syndromes (MDS) |
A Journey from Blood Cells to Genes and Back |
Aug 2023 |
Annual Review of Genomics and Human Genetics |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
Phase II trials of zilucoplan in paroxysmal nocturnal hemoglobinuria |
Aug 2023 |
Haematologica |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
Factor B inhibitor iptacopan for the treatment of paroxysmal nocturnal hemoglobinuria |
Jul 2023 |
Blood Reviews |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
Efficacy and safety of the C5 inhibitor crovalimab in complement inhibitor-naive patients with PNH (COMMODORE 3): A multicenter, Phase 3, single-arm study |
Jul 2023 |
American Journal of Hematology |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
Are we ready to ring in a new upfront therapy in lower-risk myelodysplastic syndromes? |
Jul 2023 |
Lancet |
Myelodysplastic Syndromes (MDS) |
Efficacy and safety of luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): interim analysis of a phase 3, open-label, randomised controlled trial |
Jul 2023 |
Lancet |
Myelodysplastic Syndromes (MDS) |